Oncopeptides: Positive Momentum - Redeye
Bildkälla: Stockfoto

Oncopeptides: Positive Momentum - Redeye

Redeye is growing more optimistic about the investment case in Oncopeptides after two news items this week: the inclusion of Pepaxti in the EHA-EMN guidelines and strong sales growth in Q2.

Redeye is growing more optimistic about the investment case in Oncopeptides after two news items this week: the inclusion of Pepaxti in the EHA-EMN guidelines and strong sales growth in Q2.
Börsvärldens nyhetsbrev